227 related articles for article (PubMed ID: 19939424)
1. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
Queiroga FL; Pires I; Lobo L; Lopes CS
Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
[TBL] [Abstract][Full Text] [Related]
2. Expression of Cox-1 and Cox-2 in canine mammary tumours.
Queiroga FL; Alves A; Pires I; Lopes C
J Comp Pathol; 2007; 136(2-3):177-85. PubMed ID: 17416236
[TBL] [Abstract][Full Text] [Related]
3. Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival.
Lavalle GE; Bertagnolli AC; Tavares WL; Cassali GD
Vet Pathol; 2009 Nov; 46(6):1275-80. PubMed ID: 19605908
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
[TBL] [Abstract][Full Text] [Related]
5. COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy.
Belshaw Z; Constantio-Casas F; Brearley MJ; Dunning MD; Holmes MA; Dobson JM
Vet Comp Oncol; 2011 Jun; 9(2):141-8. PubMed ID: 21569199
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
Heller DA; Clifford CA; Goldschmidt MH; Holt DE; Shofer FS; Smith A; Sorenmo KU
Vet Pathol; 2005 Nov; 42(6):776-80. PubMed ID: 16301573
[TBL] [Abstract][Full Text] [Related]
7. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
Queiroga FL; Perez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
Anticancer Res; 2005; 25(6B):4269-75. PubMed ID: 16309227
[TBL] [Abstract][Full Text] [Related]
8. Prognostic status of p53 gene mutation in canine mammary carcinoma.
Wakui S; Muto T; Yokoo K; Yokoo R; Takahashi H; Masaoka T; Hano H; Furusato M
Anticancer Res; 2001; 21(1B):611-6. PubMed ID: 11299814
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables.
Matos AJ; Lopes C; Carvalheira J; Santos M; Rutteman GR; Gärtner F
J Comp Pathol; 2006; 134(2-3):182-9. PubMed ID: 16545841
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
[TBL] [Abstract][Full Text] [Related]
11. COX-2 expression in canine normal and neoplastic mammary gland.
Dias Pereira P; Lopes CC; Matos AJ; Santos M; Gärtner F; Medeiros R; Lopes C
J Comp Pathol; 2009 May; 140(4):247-53. PubMed ID: 19203768
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclooxygenase-2 in neoplasms of the mammary gland in bitches.
Badowska-Kozakiewicz AM; Malicka E
Pol J Vet Sci; 2010; 13(2):337-42. PubMed ID: 20731190
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
15. Concurrent expression of cyclo-oxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours.
Guimarães MJ; Carvalho MI; Pires I; Prada J; Gil AG; Lopes C; Queiroga FL
J Comp Pathol; 2014 Jan; 150(1):27-34. PubMed ID: 24060154
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
17. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of regional lymph node status in canine mammary carcinomas.
Szczubiał M; Łopuszynski W
Vet Comp Oncol; 2011 Dec; 9(4):296-303. PubMed ID: 22077411
[TBL] [Abstract][Full Text] [Related]
19. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Millanta F; Citi S; Della Santa D; Porciani M; Poli A
Breast Cancer Res Treat; 2006 Jul; 98(1):115-20. PubMed ID: 16538539
[TBL] [Abstract][Full Text] [Related]
20. Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Knottenbelt C; Mellor D; Nixon C; Thompson H; Argyle DJ
J Small Anim Pract; 2006 Apr; 47(4):196-200. PubMed ID: 16573762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
